Treatment of atopic dermatitis with pimecrolimus - impact on quality of life.

about

Treatment of atopic dermatitis with pimecrolimus - impact on quality of life.

Item

http://www.wikidata.org/entity/Q38536150

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Treatment of atopic dermatitis with pimecrolimus - impact on quality of life.

@en

type

Item

label

Treatment of atopic dermatitis with pimecrolimus - impact on quality of life.

@en

prefLabel

Treatment of atopic dermatitis with pimecrolimus - impact on quality of life.

@en

P1476

Treatment of atopic dermatitis with pimecrolimus - impact on quality of life

@en

P2093

Hae-Hyuk Lee

http://www.w3.org/2001/XMLSchema#string

Margitta Worm

http://www.w3.org/2001/XMLSchema#string

Torsten Zuberbier

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children.

Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug.

Pimecrolimus does not affect Langerhans cells in murine epidermis.

Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus.

Treatment of paediatric atopic dermatitis with pimecrolimus (Elidel, SDZ ASM 981): impact on quality of life and health-related quality of life.

Elidel (pimecrolimus) cream 1%: a nonsteroidal topical agent for the treatment of atopic dermatitis.

Safety and efficacy of topical calcineurin inhibitors in the treatment of childhood atopic dermatitis.

Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis.

Discovery of topical calcineurin inhibitors and pharmacological profile of pimecrolimus.

Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents.

P304

1021-1026

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Torsten Zuberbier

Margitta Worm

P577

2007-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18516272

http://www.w3.org/2001/XMLSchema#string

P932

2387301

http://www.w3.org/2001/XMLSchema#string